Cochrane Renal Group

 Back
autoid 23
crg_id CRG090500012
titleoftrial Spinal-Injured Neuropathic Bladder Antisepsis (SINBA) Trial
acronymnoftrial SINBA
website http:www.medicalinformatics.net
identificationno
leadprefix Dr
leadsurname Lee
leadgivennames Bon San Bonne
leadposition Staff Specialist
leaddepartment Spinal Medicine Department
leadorganisation Prince of Wales Hospital Sydney
leadaddress The Prince of Wales Hospital, level 2 High Street entrance Randwick Sydney NSW 2031 Australia
leademail blee@medicalinformatics.net
leadphone +61 2 90164684
leadfax +61 2 9382 5602
leadsuffix
contactprefix Dr
contactsurname Lee
contactgivennames Bon San Bonne
contactposition Staff Specialist
contactdepartment Spinal Medicine Department
contactorganisation Prince of Wales Hospital
contactaddress The Prince of Wales Hospital, level 2 High Street entrance Randwick Sydney NSW 2031 Australia
contactemail blee@medicalinformatics.net
contactphone +61 2 90164684
contactfax +61 2 9382 5602
funding industry
otherfunding Insurance industry
fundingnameofsponsors Motor Accident Authority NSW (financial),Brucia Pharmaceutical (non financial)
ethicsapproval yes
studytype randomised
studytype_other
groupassignment
blinding_patients yes
blinding_investigators yes
blinding_outcomes yes
blinding_analysts yes
proposedstart 2000
actualstart
proposedcompletiondate 2003
actualcompletiondate
multi_center_study yes
numberofcentres 3
multi_national_study no
countrycentres Australia
researchquestion Do the Urinary Antiseptics Methenamine Hippurate or Crancerry prevent Urinary Tract Infections in people with Spinal Cord Injuries
study_status_recruitment Recruitment completed
study_status_recruitment_follow Completed
healthcarecondition Urinary Tract Infection
intervention1 Methenamine Hippurate and Cranberry Placebo
intervention2 Cranberry and Methenamine Hippurate Placebo
intervention3 Cranberry Placebo and Methenamine Hippurate Placebo
intervention4 Methenamine Hippurate and Cranberry
participants_gender both
participants_other adults
age N/A
totalrecruitment 350
inclusion The eligibility criteria for the trial were: spinal cord injury with neurogenic bladder; stable bladder management with either indwelling urethral or suprapubic catheter, intermittent catheterization, or reflex voiding with or without a condom drainage device; absence of complex urological or serious renal or hepatic pathology; not being prescribed antibiotics at the time of enrolment and absence of symptoms of a urinary tract infection at the time of enrolment. Patients had to be willing to stop any intercurrent urinary antiseptics prior to entering the trial. Patients were ineligible if they had a previous allergy to any of the tested interventions.
exclusion Patients had to be willing to stop any intercurrent urinary antiseptics prior to entering the trial. Patients were ineligible if they had a previous allergy to any of the tested interventions. (See also Inclusion criteria)
primaryoutcomes The primary endpoint was an occurrence of a symptomatic urinary tract infection
secondaryoutcomes Secondary outcome measures were bacteriological urinary analysis at time of primary endpoint and adverse events
reference Bon San Bonne Lee, Mark Haran, Lianne Hunt, Judy Simpson, Obayd Marial, Sue Rutkowski, James Middleton, George Kotsiou, Mark Tudehope. Spinal-Injured Neuropathic Bladder Antisepsis (SINBA) Trial. 43rd ISCos 2004, Annual Scientific Meeting, Sept 26-29 2004, Athens Greece
Lee BB, Haran MJ, Hunt LM, Simpson JM, Marial O, Rutkowski SB, Middleton JW, Kotsiou G, Tudehope M, Cameron ID Spinal-injured neuropathic bladder antisepsis (SINBA) trial. Spinal Cord 2006; 1-9 [advanced online publication Oct 17 2006]. doi:10.1038/sj.sc.3101974).Print publication: Spinal Cord 45, August 2007 pages 542-550.